Harris Communications Group founder and managing director Anita Harris recently covered two panel discussions on behalf of Informa/EBD Group at BioPharm America, a partnering event held in conjunction with Boston Biotech Week, at the Boston Convention Center.

In the first discussion, “2020 and beyond, “ panelists described technology  breakthroughs they believe are  likely to transform medicine in the next 10 years.

On the second panel, “AI Applications for Drug Discovery and Development, “representatives from six companies–startups, mid-sized companies and big pharma– outlined their successes and challenges in using artificial intelligence (AI) and machine learning  to discover new drug targets and biological disease markers; find molecules that can optimally modify  those markers, and to determine, in clinical trials, which treatments will best combat disease in particular patents.

The panel was moderated by  Yizhen Dong,  principal at 11.2 Capital, a San Francisco seed stage venture firm investing in… emerging technologies, including application of AI in healthcare & life sciences.”

The panelists were: Ron Alfa, senior vice president of translational discovery and chief evangelist  at Salt-Lake-City-based Recursion Pharmaceuticals;  Martin Akerman, chief technology officer and co-founder of Envisagenics, Inc., of New York City;  Heather Arnett, vice president of research at NuMedii, Inc., in San Mateo;  Joseph Szustakowski, Executive Director of Translational Bioinformatics at the global pharmaceutical company Bristol Myers Squibb, and Shanrong Zhao, director of computational biology at Pfizer, Inc., which is also global.

Here’s a link to the complete article, which is posted on the BioPharm America Website.
–Anita M. Harris